2025
Buprenorphine versus full agonist opioids for acute postoperative pain management: a systematic review and meta-analysis of randomized controlled trials
Hickey T, Costa G, Oliveira D, Podosek A, Abelleira A, Avila-Quintero V, De Aquino J. Buprenorphine versus full agonist opioids for acute postoperative pain management: a systematic review and meta-analysis of randomized controlled trials. Regional Anesthesia & Pain Medicine 2025, rapm-2024-106014. PMID: 39753290, DOI: 10.1136/rapm-2024-106014.Peer-Reviewed Original ResearchAcute postoperative pain managementPostoperative pain managementAcute postoperative painDuration of analgesiaPain intensityPain managementRandomized controlled trialsRisk of biasAgonist opioidsPostoperative painControlled trialsRescue analgesiaMeta-analysis of randomized controlled trialsMean duration of analgesiaRescue analgesia useLong duration of actionCochrane Central Register of Controlled TrialsSafety of buprenorphineCentral Register of Controlled TrialsMeta-analysisRegister of Controlled TrialsRandom-effects meta-analysisAdverse effectsDuration of actionCochrane Central Register
2024
Buprenorphine: An anesthesia-centric review.
Hickey T, Acampora G. Buprenorphine: An anesthesia-centric review. Journal Of Opioid Management 2024, 20: 503-527. PMID: 39775451, DOI: 10.5055/jom.0901.Peer-Reviewed Original ResearchConceptsOpioid use disorderEffective analgesic alternativeEffective opioid analgesicOpioid-tolerant patientsMultimodal analgesia strategyLong duration of actionPatients prescribed buprenorphineChronic pain managementDiscontinuation of buprenorphineFormulation of buprenorphineDuration of actionAnalgesic alternativeContinuing buprenorphineDose adjustmentNonopioid analgesicsAnalgesia strategyOpioid analgesicsChronic painImprove patient outcomesTemporary discontinuationPerioperative painPain managementPerioperative periodBuprenorphineUse disorder
2023
Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines
Humphrey S, Dover J, Bowsher R, Clancy A, Liu Y, Prawdzik G, Gallagher C. Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines. Aesthetic Surgery Journal 2023, 43: 1189-1193. PMID: 37051886, PMCID: PMC10501746, DOI: 10.1093/asj/sjad101.Peer-Reviewed Original ResearchConceptsClinical responseTreatment cyclesDuration of clinical responseOpen-label safety studyGlabellar line treatmentSingle-dose studyBotulinum toxin type A formulationsComplete treatment failureDuration of actionDouble-blindPlacebo-controlledTreatment failureLine treatmentAnalysis populationClinical efficacyDaxibotulinumtoxinAGlabellar linesWeek 4PatientsImmunogenic potentialAntibody formationClinical practiceBinding antibodiesAntibodiesSafety studies
2018
Preclinical Pharmacology in the Rhesus Monkey of CW 1759-50, a New Ultra-short Acting Nondepolarizing Neuromuscular Blocking Agent, Degraded and Antagonized by L-Cysteine.
Savarese JJ, Sunaga H, McGilvra JD, Belmont MR, Murrell MT, Jeannotte E, Cooke FE, Wastila WB, Heerdt PM. Preclinical Pharmacology in the Rhesus Monkey of CW 1759-50, a New Ultra-short Acting Nondepolarizing Neuromuscular Blocking Agent, Degraded and Antagonized by L-Cysteine. Anesthesiology 2018, 129: 970-988. PMID: 30212413, DOI: 10.1097/aln.0000000000002408.Peer-Reviewed Original ResearchConceptsNeuromuscular blocking agentsMean arterial pressureBlocking agentArterial pressureNeuromuscular blockadeHeart rateNew neuromuscular blocking agentRhesus monkeysNondepolarizing neuromuscular blocking agentDuration of actionStudy of bolusCirculatory effectsPreclinical pharmacologyControl infusionInstitutional Animal CareED95Large dosesSpontaneous recoveryGantacuriumDose ratioL-cysteineInfusionBolusUse CommitteeRecovery intervalDexamethasone-Related Perineal Burning in the Prehospital Setting: A Case Series
Dylla L, Acquisto N, Manzo F, Cushman J. Dexamethasone-Related Perineal Burning in the Prehospital Setting: A Case Series. Prehospital Emergency Care 2018, 22: 655-658. PMID: 29485338, DOI: 10.1080/10903127.2018.1440039.Peer-Reviewed Original Research
2015
The past, present, and future of basal insulins
Pettus J, Santos Cavaiola T, Tamborlane WV, Edelman S. The past, present, and future of basal insulins. Diabetes/Metabolism Research And Reviews 2015, 32: 478-496. PMID: 26509843, DOI: 10.1002/dmrr.2763.Peer-Reviewed Original ResearchConceptsInsulin glargine 100Basal insulinGlargine 100Glycemic controlUnits/mLNew insulin glargine 300Neutral protamine Hagedorn (NPH) insulinBasal insulin peglisproNew insulin productsSimilar glycemic controlGood glycemic controlInsulin glargine 300Type 2 diabetesDuration of actionInsulin delivery techniquesGlargine 300Insulin detemirInsulin therapyInsulin degludecNew insulinsPharmacodynamic profileInsulin secretionPharmacodynamic propertiesPrandial increaseFundamental therapy
2014
Chapter 9 Prodrugs and Drug Delivery Systems
Silverman R, Holladay M. Chapter 9 Prodrugs and Drug Delivery Systems. 2014, 423-468. DOI: 10.1016/b978-0-12-382030-3.00009-x.Peer-Reviewed Original Research
2011
Dissociation between duration of action in the forced swim test in mice and nicotinic acetylcholine receptor occupancy with sazetidine, varenicline, and 5-I-A85380
Caldarone BJ, Wang D, Paterson NE, Manzano M, Fedolak A, Cavino K, Kwan M, Hanania T, Chellappan SK, Kozikowski AP, Olivier B, Picciotto MR, Ghavami A. Dissociation between duration of action in the forced swim test in mice and nicotinic acetylcholine receptor occupancy with sazetidine, varenicline, and 5-I-A85380. Psychopharmacology 2011, 217: 199-210. PMID: 21487659, PMCID: PMC3266849, DOI: 10.1007/s00213-011-2271-y.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntidepressive AgentsAzetidinesBehavior, AnimalBenzazepinesBrainData Interpretation, StatisticalDose-Response Relationship, DrugLigandsMaleMiceMice, Inbred BALB CMice, Inbred C57BLMolecular StructureMotor ActivityNicotinic AgonistsProtein BindingPyridinesQuinoxalinesReceptors, NicotinicSwimmingTime FactorsVareniclineConceptsAntidepressant-like effectsAntidepressant-like actionSwim testDuration of actionReceptor occupancyNAChR antagonist mecamylamineDihydro-β-erythroidineAcetylcholine receptor agonistRole of β2Partial agonist vareniclineSymptoms of depressionNAChR β2Antagonist mecamylamineReceptor agonistActive dosesAgonist vareniclineSazetidinePartial agonistVareniclineObjectivesThe studyBehavioral efficacyNAChRsBehavioral responsesAgonistsPromising target
1990
Clinical Use of β-Andrenoceptor Blockade in Systemic Hypertension
Nadelmann J, Frishman W. Clinical Use of β-Andrenoceptor Blockade in Systemic Hypertension. Drugs 1990, 39: 862-876. PMID: 1973382, DOI: 10.2165/00003495-199039060-00005.Chapters
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply